As there is no multidimensional instrument available that reflects the severity of benzodiazepine (BZD) dependence comprehensively, the Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ) was developed and investigated. The Bendep-SRQ, Symptom Checklist-90 (SCL-90), Schedules for Clinical Assessments in Neuropsychiatry (SCAN), and Addiction Severity Index-Revised (ASI-R) were administered to 115 general practice (GP) patients, 124 psychiatric outpatients, and 33 self-help patients who were using BZDs. Factor and Rasch analyses were applied to construct scales. Reliability assessments were made in terms of subject discriminability, item discriminability, and test-retest stability. To support the construct validity of the scales, theoretical rationales were required to explain the specific item order provided by the Rasch scale values. To assess the concurrent and discriminant validity, a matrix consisting of the above-mentioned measures was factor-analyzed. Four Rasch-homogeneous scales were delineated: problematic use, preoccupation, lack of compliance, and withdrawal. Nearly all subject discriminability, item discriminability, and test-retest results indicated good reliability. A BZD dependence factor was extracted with high loadings for the Bendep-SRQ scales and the concurrent measures. The discriminant measures had high loadings on other factors. The scalability, reliability, and validity of the Bendep-SRQ scales appeared to be good. The Bendep-SRQ shows great promise as a useful and easily manageable instrument for assessment of the severity of BZD dependence in clinical practice and scientific research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0010-440x(99)90129-3 | DOI Listing |
J Pharm Pharmacol
November 2024
Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe 650-8530, Japan.
Objectives: Benzodiazepines (BZDs) activate the γ-aminobutyric acid (GABA) subtype A (GABAA) receptors, and thus are widely used medicines for the treatment of anxiety and insomnia. For chronic use, tolerance to BZDs is a major problem. Patients with chronic insomnia that develop tolerance to BZDs lose therapeutic effects but also potentially suffer from BZD dependence resulting in BZD withdrawal.
View Article and Find Full Text PDFJ Community Hosp Intern Med Perspect
July 2024
Department of General Medicine, Nerima Hikarigaoka Hospital, Tokyo, Japan.
Introduction: Benzodiazepine (BZD) dependence and withdrawal are significant public health concerns, affecting 15-30% of regular users within 4-6 weeks of administration. Rapid BZD tapering protocols in acute care settings can mitigate withdrawal symptoms and facilitate rehabilitation, yet are challenging due to variability in patient responses.
Case Presentation: We report a case of a 67-year-old male with a history of high-dose BZD use for panic disorder and depression and recent mild ischemic stroke, presenting with worsening left lower limb paralysis.
Mymensingh Med J
October 2024
Professor Md Rafiqul Islam, Professor and Head, Department of Medicine, North Bengal Medical College, Sirajganj, Bangladesh; E-mail:
Although comprehensive epidemiological data related to long term use and abuse of benzodiazepine (BZD) in our country is scarce, undocumented clinical observation suggests that the prevalence is quite high and constitutes a significant public health problem. This cross-sectional study was carried out in the Department of Medicine, Shaheed Ziaur Rahman Medical College hospital, Bogra, from 1st October 2015 to 31st March 2016. The objectives of the study were to evaluate the indication, dosage, duration and untoward effects of use of benzodiazepine for one month or longer among the patients attending the inpatient and outpatient departments of medicine.
View Article and Find Full Text PDFOxf Med Case Reports
September 2024
Division of Geriatric Medicine, Jewish General Hospital, McGill University, 3755 Chem. de la Côte-Sainte-Catherine, Montreal, QC H3T 1E2, Canada.
Benzodiazepines (BZDs) are among the most commonly used medications due to their efficacy and rapid onset of action. Although they offer significant therapeutic benefits in treating various psychiatric and neurological conditions, their clinical utility is limited by substantial risks, including dependency and withdrawal symptoms. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) has been linked to BZD withdrawal.
View Article and Find Full Text PDFPharmacy (Basel)
July 2024
Research Group on Environmental Toxicology and Food and Drug Safety, University of La Laguna, Ofra, 38071 Canary Island, Spain.
Background: Tolerance and dependence stand out as the most relevant risks observed during benzodiazepine (BZD) treatments.
Objectives: To evaluate the degree of dependence of patients on BZD treatments using the Tyrer test; to define a profile of patients at risk of developing BZD dependence; and to discuss the role of the pharmaceutical care offered by the community pharmacy during dispensing.
Methods: Prospective cross-sectional descriptive observational study (August 2020-February 2021) involving 127 patients using BZD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!